COMPANY PROFILE

Amicus Pharma

Explore full profile

Providing research-based services to pharmaceutical and healthcare companies

Baar, SwitzerlandFounded 2013Biotech & Life Sciences

Valuation $100–250M Last recorded · 2017

Total funding $50–100M Disclosed equity funding

At a glance

Status: Operational
Founded: 2013
Headquarters: Baar, Switzerland
Open positions: None listed
Dealroom signal: 56.1/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based, Swiss DT Biotech
Client focus: b2b
Links: Website

Founder mafia, market maps, research and news connected to this company by Dealroom

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
GROWTH EQUITY VCOther financing	May 2021	$50M	—	Mérieux Equity Partners	—
DEBTDebt	Mar 2021	$57M	—	Citi · Credit Suisse · UBS	—

Amicus Pharma website traffic

Latest recorded traffic for Amicus Pharma is 100 monthly website visits, down 92.3% over the last three months.

Latest monthly visits100 3-month web change-92.3%

Monthly website visitsNov 2017–Jun 2024

Summary metrics are public; monthly history is available with a demoCompare with peers →

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ETEngimmune TherapeuticsPlatform and product development company engineering next-generation T cell receptor therapies	Allschwil, Switzerland	Operational	12	$15M	$57M
THten23 healthThe human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups for the development, manufacture, and testing of tomorrow’s medicines	Basel, Switzerland	Operational
BTBeo TherapeuticsD cardio-metabolic diseases	Zurich, Switzerland	Operational
CECellvieDeriving medicines from cells, leveraging one of the cornerstones of evolution: mitochondria	Zurich, Switzerland	Operational
CDCDR-LifeA biotechnology company pioneering a new and differentiated class of highly tumor-specific immuno-oncology therapeutics based on its proprietary antibody-based T cell engager technology	Zurich, Switzerland	Operational
MBMimiX BiotherapeuticsAcoustic biofabrication platform for shaping tissues and organ models using sound-based cell patterning	Neuchâtel, Switzerland	Operational
CECeidosDeveloping a device automatizing cancer treatment process and ensuring better outcomes for a much lower price, making this therapy accessible for a larger amount of patients	Sion, Switzerland	Operational
VTVaderis TherapeuticsA clinical stage biotechnology company focussed on the treatment of rare and orphan diseases caused by Vascular Malformations	Basel, Switzerland	Operational